Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. [Read more…]
STAT6 as a Diagnostic Marker in Solitary Fibrous Tumors and Soft Tissue Neoplasms
Accurate tumor classification guides diagnosis, prognosis, and treatment decisions. This is particularly essential when morphologically similar tumors arise from different tissue lineages. STAT6 (signal transducer and activator of transcription 6) has emerged as a valuable diagnostic marker, as its expression pattern can help distinguish specific mesenchymal neoplasms from their histologic mimics. [Read more…]
BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells.
SAN ANTONIO, TX, July 7, 2026 – BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global (BBG), today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas — marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. [Read more…]
Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs
Japanese government-certified clinic applies ISCT-compliant flow-cytometry release criteria to patient-specific adipose-derived stem cell cultures, serving patients from approximately 20 countries [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 62
- Next Page »